NCT00003516View on ClinicalTrials.gov

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 27, 1996

Primary Completion Date

March 18, 2004

Study Completion Date

March 18, 2004

Conditions
Prostate Cancer
Interventions
DRUG

Antineoplaston therapy (Atengenal + Astugenal)

Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston

Sponsors
All Listed Sponsors
lead

Burzynski Research Institute

OTHER